Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05077735 · ClinicalTrials.gov registry record · Phase 2

Stereotactic Biopsy Split-Course Radiation Therapy in Diffuse Midline Glioma, SPORT-DMG Study

A Phase 2 study of Diffuse Midline Glioma, H3 K27M-Mutant, sponsored by Mayo Clinic.

Recruiting
Registry status
Phase 2
Development phase
29
Enrollment target
2
Study locations

NCT05077735 is a Phase 2 study of Diffuse Midline Glioma, H3 K27M-Mutant that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 29 participants, below the 231-participant average among 11 other Diffuse Midline Glioma, H3 K27M-Mutant trials with a reported enrollment target (87% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05077735, a Phase 2 study of Diffuse Midline Glioma, H3 K27M-Mutant, is actively recruiting participants, sponsored by Mayo Clinic.

RECRUITING
Registry status
Phase 2
Development phase
29 participants
Enrollment target
2
Study locations

Study Summary

This phase II trial studies the clinical outcomes of hypofractionated radiation therapy in patients with diffuse midline gliomas. This study aims to change the way radiation is delivered, from giving 6 weeks of radiation all at once to giving 2 weeks of radiation. This may determine if there is a difference in the outcome of the treatment, and most importantly, the patients' quality of life.

Conditions Studied

Diffuse Midline Glioma, H3 K27M-Mutant

Interventions

  • PROCEDURE Magnetic Resonance Imaging
  • OTHER Questionnaire Administration
  • RADIATION Hypofractionated Radiation Therapy
  • PROCEDURE Positron Emission Tomography and Computed Tomography Scan

Study Locations (2)

Arizona

  • Mayo Clinic Hospital in Arizona - Phoenix

Minnesota

  • Mayo Clinic in Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 29 participants
Start Date 2021-10-11
Est. Completion 2027-10-15
Phase Phase 2

Sponsor

Mayo Clinic

2,844 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05077735

The ClinicalTrials.gov registry entry for NCT05077735 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 231-participant average among 11 other Diffuse Midline Glioma, H3 K27M-Mutant trials with a reported enrollment target (87% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Diffuse Midline Glioma, H3 K27M-Mutant appearing as the primary indexed condition, and to 4 interventions - of which Magnetic Resonance Imaging is the first listed.

NCT05077735 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Arizona, Minnesota.

Frequently Asked Questions

What is clinical trial NCT05077735 about?

NCT05077735 is a clinical study titled "Stereotactic Biopsy Split-Course Radiation Therapy in Diffuse Midline Glioma, SPORT-DMG Study". This phase II trial studies the clinical outcomes of hypofractionated radiation therapy in patients with diffuse midline gliomas. This study aims to change the way radiation is delivered, from giving 6 weeks of radiation all at once to giving 2 weeks of radiation. This may determine if there is a di...

What is the current status of trial NCT05077735?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2021-10-11. Estimated completion is 2027-10-15.

What conditions does trial NCT05077735 study?

This clinical trial studies the following conditions: Diffuse Midline Glioma, H3 K27M-Mutant.

What interventions are being tested in trial NCT05077735?

The interventions under investigation include: Magnetic Resonance Imaging (PROCEDURE), Questionnaire Administration (OTHER), Hypofractionated Radiation Therapy (RADIATION), Positron Emission Tomography and Computed Tomography Scan (PROCEDURE).

Who is sponsoring clinical trial NCT05077735?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05077735 being conducted?

This trial has 2 study locations across Arizona, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Diffuse Midline Glioma, H3 K27M-Mutant

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Diffuse Midline Glioma, H3 K27M-Mutant

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.